The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | First-line durvalumab + monalizumab in microsatellite-stable CRC

Name: First-line durvalumab + monalizumab in microsatellite-stable CRC
Uploaded: 2020-07-08T00:00:00Z
Duration: 1 min 8 s
Description: Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, explores the use of first-line durvalumab and monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (CRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)

Zev Wainberg • 8 Jul 2020

ESMO WCGIC 2020

Colorectal Cancer Gastrointestinal Cancer Antibodies Bevacizumab Cetuximab Durvalumab Monalizumab

Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, explores the use of first-line durvalumab and monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (CRC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology)